

First Participant Recruited in Peripherex (Portfolio Company) Trial in Shaarei Zedeq hospital

Peripherex, a Portfolio Company of BioLight, is proud to announce that on the 31st of January 2022 it has recruited its first participant for trial for the testing of peripheral vision impairment at Shaare Zedek hospital in Jerusalem

The main goal of the test is to make a comparison between Peripherex' product which diagnoses and monitors peripheral vision impairment using a personal computer and built-in camera vs a common vision tool currently used for measuring visual field for this type of analysis by the Zeiss Series "Humphrey Visual Field Analyzer".

To the best of the company's knowledge, the trial is expected to include up to 50 participants and is expected to assist Peripherex in developing its product, allowing its installation in major Key Opinion Leaders' clinics specializing in glaucoma throughout the US, thereby assisting Peripherex in the further development of its product. According to Peripherex, in accordance with and subject to the rate of recruitment of participants, the experiment is expected to be completed by the 2nd quarter of 2022.

Peripherex is an American private company engaged in the development of remote diagnostic and injury monitoring solutions in peripheral vision. The product performs the peripheral vision test in an easy-to-perform manner on the part of the patient, incorporating the tracking of pupil movement using a standard laptop. The test is intended for suspicion or development of glaucoma and other eye diseases affecting peripheral vision.

Peripherex was founded based on an invention by Professor Jeffrey Goldberg, who serves as Chair of Ophthalmology at the Byers Institute at Stanford University and in collaboration with the Israeli company, UMOOVE.

For more details about the company's investment in Peripherex, including terms of investment, the company's shareholding, milestones of investment and the option for additional investment, see immediate report of the Company published on TASE on July 27 2021

Forward-Looking Statement - The information and details included in this report regarding the experiment and / or regarding a product Peripherex as well as forecasts, dates, assessments and / or plans of the Company and / or Peripherex in connection with the aforesaid, Are "forward looking information" within the meaning of the Securities Law, 1968, which involves high uncertainty, and based, among other things, on third parties and many variables that the company and / or Peripherex do not have necessarily control over them, and therefore it is possible that such information and assessments, in practice will not materialize and / or will not materialize In full and / or will materialize in a manner that is materially different from what was assessed or observed in the first place, as well as the realization of non which of the risk factors as specified in section 24.4 in Chapter A of the annual report, which may affect in a manner Significant, jointly and severally, on the Company's and Peripherex assessments as aforesaid.

About BioLight

BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye diseases and their treatment. BioLight's portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplifying the enormous potential of innovation in the ophthalmological technologies. The Ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the

needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases.